Financials in USD. Standardized financial statements.
A compact view of how Northwest Biotherapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.38M | $1.38M | $1.93M | $1.68M | $1.00M | $1.29M | $2.41M | $412,000 | $336,000 | $623,000 |
| Revenue Growth? | -0.3% | -28.5% | +14.8% | +67.5% | -22.2% | -46.4% | +485.0% | +22.6% | -46.1% | 0.0% |
| Cost of Revenue? | $2.34M | $0 | $27.73M | $1.55M | $20.31M | $33.64M | $14.11M | $18.15M | $33.52M | $60.08M |
| Gross Profit? | -$959,000 | $1.38M | -$25.80M | $135,000 | -$19.30M | -$32.35M | -$11.70M | -$17.74M | -$33.18M | -$59.46M |
| Gross Margin? | -69.6% | +100.0% | -1335.3% | +8.0% | -1920.7% | -2505.5% | -485.3% | -4306.3% | -9874.7% | -9543.8% |
| Operating Expenses? | $58.95M | $67.89M | $57.44M | $68.86M | $53.71M | $54.26M | $29.87M | $45.17M | $55.01M | $19.81M |
| Operating Income? | -$59.91M | -$66.51M | -$55.51M | -$67.18M | -$52.70M | -$86.61M | -$27.46M | -$41.48M | -$54.68M | -$79.27M |
| EBITDA? | -$57.58M | -$73.64M | -$55.34M | -$97.42M | $184.72M | -$520.85M | -$17.82M | -$24.63M | -$67.16M | -$76.21M |
| Income Before Tax | -$60.70M | -$83.78M | -$62.60M | -$105.03M | $179.13M | -$529.82M | -$20.30M | -$35.79M | -$73.14M | -$80.21M |
| Income Tax Expense | $778,000 | $0 | $0 | $0 | $0 | $0 | $3.28M | $0 | $0 | $0 |
| Net Income? | -$61.48M | -$83.78M | -$62.60M | -$105.03M | $179.13M | -$529.82M | -$20.81M | -$35.79M | -$73.14M | -$80.21M |
| EPS? | $-0.04 | $-0.07 | $-0.06 | $-0.10 | $0.21 | $-0.73 | $-0.04 | $-0.12 | $-0.31 | $-0.77 |
| Diluted EPS? | $-0.04 | $-0.07 | $-0.06 | $-0.10 | $-0.06 | $-0.73 | $-0.04 | $-0.12 | $-0.31 | $-0.77 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality